► Single Plasmid Technology
AAV production using the Single Plasmid Technology is simpler and more cost-effective:
Process Simplicity
– Only one plasmid to produce
– Straightforward PEI-DNA polycomplex prep
Comparable or Higher yields
– Single plasmid systems have matched—or even exceeded—triple transfection yields
Cost Reduction
– Less DNA needed overall
– Reduced PEI usage
– One plasmid production run, savings on time and labor
No Ratio Optimization needed
– One plasmid, no ratio
Same Cloning Ability and Plasmid Yields
– Cloning efficiency and yields remain robust.
No Increased Risk for rcAAV
– Publications confirm no extra replication-competent AAV risk when RepCap and ITRs-GOI live in the same construct.
Contact us for more information
► High Producer Cell line
Current viral vector production faces significant hurdles, including low yields, scalability issues, and high costs. We are developing a high producer cell line leveraging functional genomics by integrating genomics, epigenomics, and CRISPR technology to enhance the production yields of viral vectors in the HEK-293 cell platform.
This project is backed by a £1.1 million grant from Innovate UK and the National Research Council of Canada. We are joining forces with National Research Council Canada, Revvity and Abselion to address the critical challenges in cell and gene therapy production.
News: International Consortium to revolutionize viral vector manufacturing
VVECTOR BIO, Bridging Research and Clinic
VVector Bio offers expert biomanufacturing services to accelerate the development and commercialization of novel medicines
2020 VVECTOR BIO. All Rights Reserved
